Cariprazine use in early psychosis: three case reports

Detalhes bibliográficos
Autor(a) principal: Coentre, Ricardo
Data de Publicação: 2021
Outros Autores: Saraiva, Rodrigo, Sereijo, Carolina, Levy, Pedro
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10451/50742
Resumo: Copyright © 2021 Coentre, Saraiva, Sereijo and Levy. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
id RCAP_5e743fb0134bb85af1ee362148df6f0f
oai_identifier_str oai:repositorio.ul.pt:10451/50742
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Cariprazine use in early psychosis: three case reportsCariprazineCase reportEarly interventionEarly psychosisFirst-episode psychosisSchizophreniaCopyright © 2021 Coentre, Saraiva, Sereijo and Levy. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.Objective: Cariprazine is a new atypical antipsychotic approved for the acute and maintenance treatment of schizophrenia (1, 2) and for the treatment of manic or mixed episodes associated with bipolar I disorder (1). Recently, cariprazine also got extended FDA-approval for the treatment of depressive episodes in adults with bipolar I disorder (3). The use of low doses of atypical antipsychotics is an essential component of early intervention in psychosis. For its particular performance and tolerability, cariprazine is becoming an important option for the treatment of first-episode psychosis. Method: Three patients experiencing first-episode psychosis (FEP) were successfully treated with cariprazine. Two patients were in their first months of the disease, and the third patient was in his third year after the FEP. Results: The three patients had a diagnosis of non-affective FEP, which includes schizophrenia, delusional disorder, and schizoaffective disorder. One of them was in their third year after the FEP with a predominance of negative symptoms at this stage of the disorder. All the patients were treated with cariprazine with a target dose of 3-4.5 mg/day. The three patients showed improvements in their psychosis, including a decrease in negative symptoms. No significant side effects were reported. Conclusion: Our three case reports indicate that cariprazine is an atypical antipsychotic beneficial in the treatment of early psychosis. Treatment with low doses of cariprazine could be effective and tolerable in this phase of the disorder. Future studies with longer follow-up of FEP patients are recommended to confirm these positive results of cariprazine in the early phases of psychosis.FrontiersRepositório da Universidade de LisboaCoentre, RicardoSaraiva, RodrigoSereijo, CarolinaLevy, Pedro2022-01-07T15:42:06Z20212021-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/50742engFront Psychiatry. 2021 Dec 16;12:78828110.3389/fpsyt.2021.7882811664-0640info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-08T16:55:04Zoai:repositorio.ul.pt:10451/50742Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T22:02:08.356701Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Cariprazine use in early psychosis: three case reports
title Cariprazine use in early psychosis: three case reports
spellingShingle Cariprazine use in early psychosis: three case reports
Coentre, Ricardo
Cariprazine
Case report
Early intervention
Early psychosis
First-episode psychosis
Schizophrenia
title_short Cariprazine use in early psychosis: three case reports
title_full Cariprazine use in early psychosis: three case reports
title_fullStr Cariprazine use in early psychosis: three case reports
title_full_unstemmed Cariprazine use in early psychosis: three case reports
title_sort Cariprazine use in early psychosis: three case reports
author Coentre, Ricardo
author_facet Coentre, Ricardo
Saraiva, Rodrigo
Sereijo, Carolina
Levy, Pedro
author_role author
author2 Saraiva, Rodrigo
Sereijo, Carolina
Levy, Pedro
author2_role author
author
author
dc.contributor.none.fl_str_mv Repositório da Universidade de Lisboa
dc.contributor.author.fl_str_mv Coentre, Ricardo
Saraiva, Rodrigo
Sereijo, Carolina
Levy, Pedro
dc.subject.por.fl_str_mv Cariprazine
Case report
Early intervention
Early psychosis
First-episode psychosis
Schizophrenia
topic Cariprazine
Case report
Early intervention
Early psychosis
First-episode psychosis
Schizophrenia
description Copyright © 2021 Coentre, Saraiva, Sereijo and Levy. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
publishDate 2021
dc.date.none.fl_str_mv 2021
2021-01-01T00:00:00Z
2022-01-07T15:42:06Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10451/50742
url http://hdl.handle.net/10451/50742
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Front Psychiatry. 2021 Dec 16;12:788281
10.3389/fpsyt.2021.788281
1664-0640
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Frontiers
publisher.none.fl_str_mv Frontiers
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799134570290872320

Registros relacionados